Breast Cancer Core Needle Biopsy Market

The rising incidence of breast cancer, growing awareness of early detection techniques, and technological advancements in core needle biopsy drive the global breast cancer core needle biopsy market. Minimally invasive procedures, improved diagnostic accuracy, and increasing healthcare expenditure further contribute to market growth.

Trends in recent times include the adoption of vacuum-assisted breast biopsy (VABB) for improved sample collection, advancements in ultrasound-guided core needle biopsy (US-CNB) for real-time visualization, and the emergence of automated core needle biopsy devices for enhanced precision and accuracy.

Opportunities for market expansion exist in developing regions with limited access to advanced healthcare facilities, the integration of artificial intelligence (AI) for better image analysis, and the development of molecular biomarkers to guide treatment decisions.

The Global Breast Cancer Core Needle Biopsy Market Industry is projected to experience robust growth over the next decade. With an estimated market value of 0.4 USD Billion in 2024, it is expected to reach 0.69 USD Billion by 2035, reflecting a compound annual growth rate of 5.05% from 2025 to 2035. This growth is driven by various factors, including rising breast cancer incidence, technological advancements, and increasing awareness of early detection. The market's expansion indicates a strong demand for core needle biopsy procedures, positioning it as a vital component in breast cancer diagnostics.

The increasing incidence of breast cancer globally serves as a primary driver for the Global Breast Cancer Core Needle Biopsy Market Industry. According to the World Health Organization, breast cancer remains the most commonly diagnosed cancer among women, with millions of new cases reported annually. This trend necessitates the development and adoption of effective diagnostic tools, such as core needle biopsies, which provide accurate tissue sampling. As the number of breast cancer cases rises, the demand for minimally invasive procedures like core needle biopsies is expected to grow, contributing to the market's projected value of 0.4 USD Billion in 2024 and an anticipated increase to 0.69 USD Billion by 2035.

Government initiatives aimed at combating breast cancer are playing a crucial role in shaping the Global Breast Cancer Core Needle Biopsy Market Industry. Various countries are implementing policies to enhance cancer care, including funding for research and development of diagnostic technologies. These initiatives often lead to increased accessibility of core needle biopsy procedures, making them more widely available to patients. As governments allocate resources to improve healthcare infrastructure and support cancer research, the market is likely to benefit from enhanced investment and innovation, further propelling its growth trajectory.

Growing awareness about breast cancer and the importance of early detection is driving the Global Breast Cancer Core Needle Biopsy Market Industry. Public health campaigns and screening programs are encouraging women to undergo regular mammograms and biopsies, leading to earlier diagnosis and treatment. This heightened awareness is reflected in the rising number of women participating in screening initiatives, which subsequently increases the demand for core needle biopsies. As more women are educated about their health, the market is expected to grow, aligning with the projected increase in market value from 0.4 USD Billion in 2024 to 0.69 USD Billion by 2035.

Technological innovations in biopsy techniques are significantly influencing the Global Breast Cancer Core Needle Biopsy Market Industry. Advancements such as ultrasound-guided biopsies and automated biopsy devices enhance the precision and efficiency of tissue sampling. These innovations not only improve patient outcomes but also reduce the risk of complications associated with traditional biopsy methods. As healthcare providers increasingly adopt these advanced technologies, the market is likely to experience substantial growth. The projected compound annual growth rate of 5.05% from 2025 to 2035 underscores the potential for further expansion driven by these technological advancements.

The growing preference for minimally invasive procedures among patients is a significant driver of the Global Breast Cancer Core Needle Biopsy Market Industry. Patients increasingly seek options that minimize discomfort and recovery time, making core needle biopsies an attractive choice compared to traditional surgical biopsies. This shift in patient preference is influencing healthcare providers to adopt less invasive techniques, thereby expanding the market. As the demand for patient-centered care continues to rise, the market is expected to flourish, reflecting the anticipated growth in value from 0.4 USD Billion in 2024 to 0.69 USD Billion by 2035.

The Global Breast Cancer Core Needle Biopsy Market is segmented into North America, Europe, Asia Pacific, South America, and Middle East Africa. North America is expected to hold the largest market share in 2023, owing to the high prevalence of breast cancer and the increasing adoption of core needle biopsy procedures. Europe is expected to be the second-largest market, followed by Asia Pacific.

The Asia Pacific region is expected to witness the fastest growth rate during the forecast period, due to the rising incidence of breast cancer and the increasing awareness of core needle biopsy procedures. South America and Middle East Africa are expected to contribute a smaller share to the global market.

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Major players in the Breast Cancer Core Needle Biopsy Market industry are continuously investing in research and development to enhance their product offerings and expand their market share. Leading Breast Cancer Core Needle Biopsy Market players are focused on developing innovative technologies and solutions to meet the evolving needs of healthcare professionals and patients.

The Breast Cancer Core Needle Biopsy Market development is driven by the increasing prevalence of breast cancer, advancements in medical imaging technologies, and the growing demand for minimally invasive procedures.

Hologic, Inc. is a leading player in the Breast Cancer Core Needle Biopsy Market industry. The company offers a comprehensive portfolio of breast biopsy systems and devices, including the Affirm Prone Breast Biopsy System, the Mammotome Revolve Biopsy System, and the ProCore Automated Breast Biopsy System.

Hologic, Inc. has a strong presence in both the US and international markets and is continuously investing in research and development to enhance its product offerings and expand its market share.

BD (Becton, Dickinson and Company) is another major player in the Breast Cancer Core Needle Biopsy Market industry. The company offers a wide range of biopsy systems and devices, including the Bard Magnum Core Biopsy Instrument, the Bard Max-Core Biopsy Instrument, and the Bard Precisio Core Biopsy Instrument.

BD (Becton, Dickinson and Company) has a global presence and is focused on developing innovative technologies and solutions to meet the evolving needs of healthcare professionals and patients.